Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta ‐analysis involving eight eligible randomized‐controlled trials

Journal of Cellular Physiology, EarlyView.
Source: Journal of Cellular Physiology - Category: Cytology Authors: Source Type: research

Related Links:

Publication date: 15 October 2019Source: Cell Reports, Volume 29, Issue 3Author(s): Yongxu Zhao, Zhuanghui Feng, Qiurong DingSummaryThis Matters Arising Response paper addresses the Hoch et al. (2019) Matters Arising paper published concurrently in this issue of Cell Reports. The genetic study in humans revealed a strong association of DNA variants in the SLC16A11 coding region with type 2 diabetes mellitus (T2DM). However, how these T2D variants affect the function of SLC16A11 remains controversial. In Zhao et al. (2019), with studies using genetic knockout mouse models and in vivo gene reconstitution exper...
Source: Cell Reports - Category: Cytology Source Type: research
In conclusion, Chinese postmenopausal women with T2DM had a similar risk of incident VFs, but a significantly higher risk of incident non-VF, compared to women without DM. Higher BMI did not modify the effect of T2DM on risk of VFs, but it increased the association be tween T2DM and risk of non-VFs. LS BMDT-score was similarly and negatively associated with VF risk in T2DM and non-DM women and appear to be useful for clinical evaluation of VF risk.
Source: Calcified Tissue International - Category: Orthopaedics Source Type: research
Source: Critical Reviews in Food Science and Nutrition - Category: Nutrition Authors: Source Type: research
Gestational diabetes (GDM) is a known risk factor for type 2 diabetes mellitus (T2DM), and women with a history of GDM have a 7-fold increased risk of developing the disease. Achieving a healthy weight post-de...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Study protocol Source Type: research
Abstract The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients. Three electronic databases (Pubmed, Web of Science, and Cochrane Central) were searched for all published articles evaluating the effects of liraglutide on blood pressure in subjects with type 2 diabetes mellitus. Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks. Liraglutide 1.8 mg/day reduced systolic ...
Source: Clinical and Experimental Hypertension - Category: Cardiology Authors: Tags: Clin Exp Hypertens Source Type: research
The Metabolic Syndrome may be tentatively defined as the clustering of several metabolic risk factors in the same individual. A progressively higher number of children and adolescents is affected by this syndrome worldwide, mainly as a consequence of the constant increase of the prevalence of obesity and sedentary habits. As obesity, the chance that the metabolic syndrome traks into adulthood is high. Moreover, the evidence of an association between the duration of the exposition to metabolic risk factors and morbidity and mortality justifies early treatment and prevention of the metabolic syndrome in both children and ado...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSION: GLP-1 RA therapy represents an important add-on therapy option for achieving decreased insulin doses, weight loss, and modest improvements in HbA1c levels without significantly increasing hypoglycemia risk in patients with T1DM. Patients who have detectable C-peptide and/or are overweight or cannot achieve glycemic goals without hypoglycemia have been found to benefit the most from GLP-1 RA therapy. Further studies are warranted to evaluate these agents' potential impact on clinical outcomes such as microvascular and macrovascular complications. PMID: 31612934 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Tags: Am J Health Syst Pharm Source Type: research
AbstractHeart failure is one of the major cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and increases the risk of morbidity and mortality. Although active management for heart failure is needed in patients with T2DM, traditional treatment and some new class of antihyperglycemic drugs, such as glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, could not reduce the risk of heart failure. Recent major trials demonstrated sodium –glucose co-transporter-2 (SGLT2) inhibitors improve prognosis of T2DM patients through prevention of heart failure. Both heart failur...
Source: Journal of Echocardiography - Category: Cardiology Source Type: research
Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks". Circulation. 2019 Oct 15;140(16):e724-e725 Authors: Sattar N, Rawshani A, Franzen S PMID: 31609663 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks". Circulation. 2019 Oct 15;140(16):e722-e723 Authors: Wang J, Xu Y PMID: 31609662 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
More News: Cytology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Physiology